22nd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy
October 1-4, 2020

Chairs: J. Cortes, T.P. Hughes, D.S. Krause


This program is presented according to Central European Summer Time (CEST).
Please check the corresponding hours in your time zone.

Thursday, October 1, 2020

14:00-14:10 WELCOME Jorge Cortes (Augusta)
14:10-14:20 iCMLf - A REVIEW Tim P. Hughes (Adelaide)
14:20-14:53 SPECIAL INTRODUCTORY LECTURE Chair: Jerry Radich (Seattle)
14:20-14:23 Introduction
14:23-14:43 Finding relapse-fated cells at diagnosis and targeting relapse before it evolves John Dick (Toronto)
14:43-14:53 Discussion
14:53-16:40 SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2020 Chairs: Brian Huntly (Cambridge), Francois -Xavier Mahon (Bordeaux)
14:53-14:56 Introduction
14:56-15:08 Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure Susan Branford (Adelaide)
15:08-15:20 Tgfβr - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenviroment Bac Viet Le (Warsaw/Philadelphia)
15:20-15:32 Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib Jorge Cortes (Augusta)
15:32-15:44 Deceiving and Drugging BCR-ABL1 Compound Mutants: Pairing a Conformational Influencer with Asciminib or an Asciminib Proteolysis-Targeting Chimera (PROTAC) Thomas O’Hare (Salt Lake City)
15:44-15:56 Therapeutic Inhibition of Malignant FcγrIIb-Induced BTK Activation Targets Leukemic Stem Cells in Chronic Myeloid Leukemia
Mirle Schemionek (Aachen)

15:56-16:08 Molecular Status 36 Months after TKI-Discontinuation in CML Is Highly Predictive for Later Loss of MMR - a Report from after-SKI.
Johan Richter (Lund)

16:08-16:20 Protein Transfer between CML and Bone Marrow Stromal Cells: Functional Meaning and the Involvement of Tnts
Marta Kolba (Warsaw)

16:20-16:40 Discussion

16:40-16:50 Break

16:50-16:53 Introduction

16:50-17:23 TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE
Chair: Steffen Koschmieder (Aachen)

16:53-17:13 Understanding and targeting the stem cell origins of myeloid malignancies
Ulrich Steidl (New York)

17:13-17:23 Discussion

17:23-19:10 SCIENTIFIC SESSION 2: STEM CELLS AND THE MICROENVIRONMENT
Chairs: Daniela Krause (Frankfurt) and Ram Thakur (Lund)

17:26-17:29 Introduction

17:26-17:41 Keynote Presentation
Regulation of hematopoietic stem and progenitor cells by the bone marrow microenvironment
Ralf Adams (Munster)

17:41-17:51 Discussion

Selected Abstracts

17:51-18:03 The Role of the Autophagy Adaptor Protein PLEKHM1 in the Leukaemic Bone Marrow Microenvironment
Christina Karantanou (Frankfurt)

18:03-18:15 Features of BCR-ABL1 Driven Myeloproliferative Disease in a CML Mouse Model Are Dependent on LSC Age and Fitness
Hassan Almasoudi (Glasgow)

18:15-18:27 Murine Hematopoietic and Leukemic Stem/Progenitor Cell Lines As Model Systems for Bcr/Abl Driven Disease
Veronika Sexl (Vienna)

18:27-18:39 Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Drug-Resistant CML Stem/Progenitor Cells
Andrew Wu (Vancouver)

Benjamin Lebecque (Clermont-Ferrand)

18:51-19:10 Discussion
19:10-19:50 JANET ROWLEY PRIZE CEREMONY
19:10-19:20 JANET ROWLEY PRIZE PRESENTATION
   Presenter: Rob Welner (Birmingham)
   Awardee 2020: Ravi Bhatia (Birmingham)
19:20-19:40 JANET ROWLEY PRIZE: SPECIAL LECTURE (2)
   Chair: Rob Welner (Birmingham)
   The seed and the soil – the leukemia stem cell in its niche and the quest for cure Ravi Bhatia (Birmingham)
19:40-19:50 Discussion

Friday, October 2, 2020

11:30-12:15 SCIENTIFIC SESSION 3: IMMUNOLOGY AND INFLAMMATION
   Chair: Shinya Kimura (Saga)
   Introduction
   Selected Abstracts
11:33-11:45 Sterile Inflammation in Normal Hematopoiesis and Leukemia Pablo Llavona (Frankfurt)
11:45-11:57 Immunosuppressive Polarization of T Cell Subsets in Spleen and Bone Marrow of Mice with CML-like Disease Julian Swatler (Warsaw)
11:57-12:15 Discussion
12:15-14:00 Lunch

13:00-14:00 SATELLITE SYMPOSIUM:
   RECENT HIGHLIGHTS IN CML: WHAT HAVE WE LEARNED IN 2020?
   Chair: Philippe Rousselot (France)
   Speakers: Mario Tiritelli (Italy), Jorge Cortes (USA)
   This educational symposium is organized and funded by Incyte Biosciences International Sàrl

14:00-15:33 SCIENTIFIC SESSION 4: THE BIOLOGY OF BLAST PHASE
   Chair: Adam Mead (Oxford)
   Introduction
   Keynote Presentation Daniel Bolon (Amherst)
   CRISPR predictions about relapse in CML
   Discussion
   Selected Abstracts
14:28-14:40 RUNX1 Mutations in Blast Phase Chronic Myeloid Leukemia Shady Adnan Awad (Helsinki)
14:40-14:52  H3K36ME3 Loss in Chronic Myeloid Leukemia Patients in Blast Crisis Is Mediated by an Unbalanced SETD2/KDM4A Activity and CAN be Therapeutically Targeted  Manuela Mancini (Bologna)

14:52-15:04  Releasing the Brakes on Apoptosis: Investigating Combinations of BH3 Mimetics and Nilotinib in Blast Phase CML  Narissa Parry (Glasgow)

15:04-15:16  Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias  Eleonora Mäkelä (Turku)

15:16-15:33  Discussion

15:35  **Biology Posters - Mentored Poster Walk 1**

*Biology Poster Walk Leaders:* Sin Tiong Ong (Singapore), Stéphane Prost (Fontenay-aux-Roses)

15:35 – 16:35  **CONCURRENT MEET-THE-EXPERT SESSIONS** (pre-registration required)

- Clinical trial design  Donald Berry (Houston) and Joëlle Guilhot (Poitiers)
- New drugs under development  Jorge Cortes (Augusta) and Tim Hughes (Adelaide)

16:35-16:45  **Convene in the Main Conference Hall**

16:45 -18:20  **SPECIAL SYMPOSIUM ON ONCOIMMUNOLOGY IN HEMATOLOGIC MALIGNANCIES**  
*Chairs:* Jorge Cortes (Augusta), Kimmo Porkka (Helsinki)

16:45-16:55  Introductory overview – concepts and challenges

16:55-17:07  *Leukemia vaccines*  David Scheinberg (New York)

17:07-17:19  *Past, present and future of CAR-T cell therapy for AML?*  Saar Gill (Philadelphia)

17:19-17:31  *Bi-specific and allogeneic CAR-T*  Xianxin Hua (Philadelphia)

17:31-17:43  *Checkpoint inhibitors*  Justin Kline (Chicago)

17:43-17:55  *Bispecific antibodies in myeloid leukemias*  Roland Walter (Seattle)

17:55-18:20  General Discussion

18:20-18:53  **SPECIAL LECTURE (3):**  
*Chair:* Rick Van Etten (Irvine)

18:20-18:23  *Introduction*

18:23-18:43  *CML blast crisis and the microenvironment*  Tannishtha Reya (San Diego)

18:43-18:53  *Discussion*
**Saturday, October 3, 2020**

### 08:50-10:50
**WORKSHOP FOR NON-CLINICAL SCIENTISTS #1**
**PROTEOMICS / SECRETOMICS**
*Chairs:* Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:50-08:55</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)</td>
</tr>
<tr>
<td>08:55-09:20</td>
<td>An integrated platform for biomarker and drug target discovery using proteomics</td>
</tr>
<tr>
<td></td>
<td>Anthony Whetton (Manchester)</td>
</tr>
<tr>
<td>09:20-09:45</td>
<td>MS-proteomics to uncover the complexity and function of the cell secretome</td>
</tr>
<tr>
<td></td>
<td>Sara Zanivan (Glasgow)</td>
</tr>
<tr>
<td>09:45-10:10</td>
<td>Investigating secretome and sheddome composition with proteomic approaches</td>
</tr>
<tr>
<td></td>
<td>Oliver Schilling (Freiburg)</td>
</tr>
<tr>
<td>10:10-10:40</td>
<td><em>Discussion</em></td>
</tr>
<tr>
<td>10:40-10:50</td>
<td>Conclusion</td>
</tr>
</tbody>
</table>

### 11:00-11:40
**JOHN GOLDMAN PRIZE CEREMONY**

**JOHN GOLDMAN PRIZE PRESENTATION**
*Presenter:* Hemant Malhotra (Jaipur)
*Awardee 2020:* Jane Apperley (London)

**JOHN GOLDMAN PRIZE: SPECIAL LECTURE (4)**
*Chair:* Hemant Malhotra (Jaipur)
*CML and me: reflections on the roadmap to cure* 
*Jane Apperley (London)*

*Discussion*

### 11:40-13:10
**SCIENTIFIC SESSION 5: NEW TREATMENT STRATEGIES**
*Chair:* Gianantonio Rosti (Bologna)

**Introduction**

**Keynote Presentation**
*Citius, Altius, Fortius ?* 
*Andreas Hochhaus (Jena)*

*Discussion*

**Selected Abstracts**

**A Novel Oral Demethylating Agent, or-2100, in Combination with Tyrosine Kinase Inhibitors Overcomes Resistance in Chronic Myeloid Leukemia** 
*Kazuharu Kamachi (Saga)*
12:20-12:32  Targeting Integrated Stress Response Combined with Imatinib As a Novel Strategy to Eradicate Imatinib-Resistant CML Cells
Katarzyna Piwocka (Warsaw)

12:32-12:44  Activity of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib
Jorge Cortes (Augusta)

12:44-12:56  Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study
Sung-Hyun Kim (Busan)

12:56-13:10  Discussion

13:10-14:50  Lunch

13:20-14:50  SATELLITE SYMPOSIUM: TRAVELING THROUGH THE UNSOLVED NEEDS IN CML: TOWARDS NEW STRATEGIES
Chair: Andreas Hochhaus (Jena)
Speakers: Valentin Garcia-Gutiérrez (Madrid), Massimo Breccia (Roma), Delphine Réa (Paris)

This educational symposium is organized and funded by Novartis Oncology

14:50-15:00  Convene in the Main Conference Hall

15:00-15:20  ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY

15:00-15:10  Presenter: Hervé Dombret (Paris), ESH President

15:10-15:20  Awardee 2020: Vaidehi Krishnan (Singapore)
High dimensional single-cell analysis to predict TFR at the time of CML diagnosis

15:20-16:55  SCIENTIFIC SESSION 6: TREATMENT-FREE REMISSION
Chair: Dragana Milojkovic (London)

15:20-15:23  Introduction

15:23-15:38  Keynote Presentation
Strategies for optimal TFR rates in CML
Susanne Saussele (Mannheim)

15:38-15:48  Discussion

15:48-16:00  Selected Abstracts
The rate of BCR-ABL1 decline after TKI commencement is a strong predictor of sustained Treatment Free Remission
Naranie Shanmuganathan (Adelaide)

16:00-16:12  High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry
Johan Richter (Lund)
16:12-16:24  Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients
Katia Pagnano (Campinas)

16:24-16:36  Update of the French Spirit Trial with a Detailed Focus on Treatment Free Remission
François Guilhot (Poitiers)

16:36-16:55  Discussion

16:55-17:05  Break

17:05-18:50  SCIENTIFIC SESSION 7: TREATMENT-FREE REMISSION - PREDICTIVE FACTORS
Chair: Delphine Réa (Paris)

17:08-17:23  Keynote Presentation
Successful TFR in CML: is it predictable?
Agnes Yong (Adelaide)

17:23-17:33  Discussion

Selected Abstracts

17:33-17:45  BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Early Predictive Surrogate for Treatment-Free Remission Failure after Imatinib Discontinuation
Dennis Kim (Toronto)

17:45-18:09  Chronic Myeloid Leukemia Patients’ Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions
Giora Sharf (Netanya)

17:57-18:09  Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia
Robert Gale (London)

18:09-18:21  Risk Factor Analysis for Treatment-Free Remission Failure after Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase: The Optimal Duration of Total Imatinib Treatment and MR4 Response
Dennis Kim (Toronto)

18:21-18:33  Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study
Frédéric Millot (Poitiers)

18:33-18:50  Discussion

18:50-19:23  SPECIAL LECTURE (S):
Chair: Giovanni Martinelli (Meldola)

18:50-18:53  Introduction

18:53-19:13  Human evolutionary genomic medicine
Melissa Ilardo (Salt Lake City)

19:13-19:23  Discussion
Sunday, October 4, 2020

14:30-16:30 WORKSHOP FOR NON-CLINICAL SCIENTISTS #2
ARTIFICIAL INTELLIGENCE / MACHINE LEARNING
Chairs: Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)

14:30-14:35 Introduction
  Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)

14:35-15:00 Long-term single-cell quantification: new tools for old questions
  Timm Schroeder (Basel)

15:00-15:25 Computational Pathology: Towards Precision Medicine
  Andrew Janowczyk (Cleveland)

15:25-15:50 Learning to Care: Artificial Intelligence Meets Clinical Practice
  Jeffrey Humpherys (Salt Lake City)

15:50-16:20 Discussion

16:20-16:30 Conclusion

14:30 – 15:30 CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

Understanding and analyzing the new ELN recommendations
  Andreas Hochhaus (Jena) and Michael Mauro (New York)

15:30-16:30 Clinical Posters - Mentored Poster Walk 2
Clinical Poster Walk Leaders: Franck Nicolini (Lyon), Pierre Laneuville (Montreal)

16:30- 17:03 SPECIAL LECTURE (6):
Chair: Catriona Jamieson (La Jolla)

16:30-16:33 Introduction

16:33-16:53 Single cell RNA sequencing in MPN
  Bethan Psaila (Oxford)

16:53-17:03 Discussion

17:03-18:20 DEBATE: “SWITCH TO A MORE POTENT DRUG TO GAIN ELIGIBILITY FOR TFR?”
Chair: Philippe Rousselot (Versailles)

17:03-17:06 Introduction

17:06-17:10 Voting

17:10-17:30 Against: Charles Schiffer (Detroit)

17:30-17:50 For: Giuseppe Saglio (Turin)

17:50-18:20 Voting and Discussion
18:20-19:00  **iCMLf PRIZE CEREMONY**

18:20-18:30  **iCMLf PRIZE PRESENTATION:**
*Presenter:* Jerry Radich (Seattle)
*Awardee 2020:* Sabira Kurtovic (Sarajevo)

18:30-18:50  **iCMLf PRIZE: SPECIAL LECTURE (7)**
*Chair:* Jerry Radich (Seattle)

CML management in war and peace: lessons that shaped future approaches

Sabira Kurtovic (Sarajevo)

18:50-19:00  *Discussion*

19:00-20:20  **SCIENTIFIC SESSION 8: TKI SAFETY**
*Chair:* Javier Pinilla-Ibarz (Tampa)

19:00-19:03  *Introduction*

19:03-19:18  **Keynote presentation**
*Novel trial designs*  
Donald Berry (Houston)

19:18-19:28  *Discussion*

19:28-19:40  **Selected Abstracts**

*Cellular Metabolic Flexibility to Explain Interindividual Susceptibility for Tyrosine Kinase Inhibitor-Induced Muscle Complaints*  
Lando Janssen (Nijmegen)

19:40-19:52  *Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia*  
James Januzzi (Boston)

19:52-20:04  *High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study*  
Massimo Breccia (Rome)

20:04-20:20  *Discussion*

20:20  **Closing remarks**